Akriderm, 0.05% cream 15 g

Pharmacotherapeutic group: glucocorticosteroid for topical use

ATX code: D07AC01

Pharmacological action

The corticosteroid betamethasone dipropionate has anti-inflammatory, anti-allergic, anti-exudative, anti-edema and antipruritic effects. It inhibits leukocyte accumulation, release of lysosomal enzymes and anti-inflammatory mediators in the inflammation focus, inhibits phagocytosis, reduces vascular and tissue permeability and prevents formation of inflammatory edema.

Indications

– Allergic skin conditions (including. Acute, subacute and chronic contact dermatitis, occupational dermatitis, sun dermatitis, neurodermatitis, skin itching, dyshidrotic dermatitis);

– acute and chronic forms of non-allergic dermatitis;

– psoriasis.

Active ingredient

Composition

How to take, the dosage

Externally. Acriderm® is applied thinly to the affected area of the skin twice a day – in the morning and in the evening. Other frequency of application can be determined by a doctor, depending on the severity of the disease. In mild cases, once a day is usually enough; more frequent application might be necessary.

The duration of treatment depends on the effectiveness and tolerability of the therapy and is 2-4 weeks.

If there is no clinical improvement, the diagnosis needs to be clarified.

Interaction

No clinically reliable interactions with other medicinal products have been observed.

Special Instructions

If there are signs of hypersensitivity or skin irritation associated with the use of the drug, treatment should be discontinued and the patient should find an adequate therapy. During prolonged treatment, when applying the drug to large surfaces of the skin, when using occlusive dressings, as well as in children, systemic absorption of glucocorticosteroids is possible.

In children from 1 year of age the drug is prescribed only with strict indications and under medical supervision, because of possible systemic side effects associated with betamethasone. When using the drug on large surfaces and/or under occlusive dressing suppression of hypothalamic-pituitary-adrenal system function and development of hypercorticism symptoms may occur, reduction of growth hormone excretion and increased intracranial pressure may be observed.

Atrophic changes may occur on the facial skin more frequently than on other body surfaces after long-term treatment with topical glucocorticosteroids; in this case the course of treatment should not exceed 5 days.

Acriderm® cream is not suitable for use in ophthalmology. Avoid contact of the drug with the eyes.
If the drug is used for a long time, it should be withdrawn gradually.

Acriderm® Cream is not intended for use in ophthalmology.

Contraindications

Hypersensitivity to any of the ingredients of the drug, bacterial, fungal skin diseases, skin tuberculosis, cutaneous syphilis, varicella, herpes simplex, skin postvaccinal reactions, open wounds, trophic ulcers of the shin, rosacea, acne vulgaris, skin cancer, nevi, atheroma, melanoma, hemangioma, xanthoma, sarcoma, lactation and children under 1 year old.

With caution

Pregnancy. With long-term use or application on large surfaces: cataracts, diabetes mellitus, glaucoma, tuberculosis.

Side effects

When glucocorticosteroids are used topically there may be: burning, irritation, dry skin, folliculitis, hypertrichosis, acne-like rashes, skin itching, stretch marks, sweating, hypopigmentation, perioral dermatitis.

Long-term use, as well as use of occlusive dressings causes skin maceration, secondary infection, skin atrophy, sweating, purpura, local hirsutism, telangiectasia. When applied to large body surfaces, mainly in children, systemic side effects of glucocorticosteroids may occur (gastritis, ulceration of the mucosa of the gastrointestinal tract, hyperglycemia, glucosuria, reversible suppression of adrenal cortical function, manifestation of Cushing’s syndrome).

In case of any adverse reactions not described in the instructions, consult a physician.

Overdose

Acute overdose is unlikely; however, with excessive or prolonged use of the drug, chronic overdose is possible, accompanied by signs of hypercorticism: hyperglycemia, glucosuria, reversible suppression of adrenal cortical function, manifestation of Cushing’s syndrome.

Treatment. Appropriate symptomatic treatment is indicated. In case of chronic toxic effects, gradual withdrawal of the drug is recommended.

Pregnancy use

Similarities